BioSpace News Archive

Nordic Nanovector ASA (OSE: NANO) announces that members of its senior management team will participate and present at the following upcoming investor conferences during November and December

BIOLASE, Inc., the global leader in dental lasers, announced it appointed Michael DiTolla, DDS, FAGD to its board of directors, effective November 14, 2019.

Merck Animal Health, a division of Merck & Co., Inc., Kenilworth, N.J., USA (NYSE: MRK), today announced the U.S. approval of BRAVECTO® PLUS topical solution for cats by the U.S. Food and Drug Administration (FDA).

Applied Therapeutics Inc. (Nasdaq:APLT), today announced the presentation of data at the American Heart Association (AHA) Scientific Sessions 2019 in Philadelphia (November 16-18, 2019) on AT-001, a novel, potent and selective aldose reductase inhibitor (ARI) in Phase 3 clinical development for Diabetic Cardiomyopathy (DbCM).

resTORbio, Inc., (Nasdaq: TORC), a clinical-stage biopharmaceutical company developing innovative medicines that target the biology of aging to prevent or treat aging-related diseases, today announced that top line data from the PROTECTOR 1 Phase 3 study, evaluating the safety and efficacy of RTB101 in preventing clinically symptomatic respiratory illness (CSRI) in adults age 65 and older,

Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF) has provided preliminary, unaudited financial results for the third quarter of 2019 for its BC-based, 50%-owned joint venture, Pure Sunfarms (“PSF”). The Company will report complete financial results for the third quarter ended September 30, 2019, after market close on Friday

Bruker Corporation announced it will present at the following conferences

Centene Corporation announced that it has commenced an offering to sell $7,000,000,000 of senior notes.

T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company,”“T2,” or “T2 Biosystems”), a leader in the development and commercialization of innovative medical diagnostic products for critical unmet needs in healthcare, announced today that John McDonough, chairman and chief executive officer, and John Sprague, chief financial officer, are scheduled to present at the 13th Annual Canaccord Genuity Medical Technology & Diagnostics Forum

RedHill Biopharma Ltd. announced that it will voluntarily delist its ordinary shares from trading on the Tel Aviv Stock Exchange